Bulletin
Investor Alert

press release

Feb. 23, 2021, 7:00 a.m. EST

Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster™ for the development of Luminary's CAR-T cell therapies

MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ -- Bio-Techne Corporation /zigman2/quotes/203973516/composite TECH -0.03% today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster [™] for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.  

Under the terms of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will use TcBuster in their LMY-920 program, a BAFF-CAR-T product. Luminary Therapeutics plans to file an IND with the FDA later this calendar year.

"This agreement with Luminary Therapeutics brings Bio-Techne's cutting-edge TcBuster system one step closer to delivering gene-modified cell therapies," said Dave Eansor, President of Bio-Techne's Protein Sciences Segment. "With this license agreement, Bio-Techne will increase its presence as a key player in the cell and gene therapy market."

"The use of TcBuster during the manufacturing process provides significant benefits over the current viral approaches allowing for delivery of larger cargo with safe integration profiles," said John Hurley, Luminary Therapeutics' COO. "We are excited to utilize GMP grade TcBuster reagents to provide our patients with a cutting-edge next generation CAR-T therapy."

More information on the TcBuster and other genome engineering services can be found at  www.rndsystems.com/products/genome-engineering .

About Bio-Techne Corporation   /zigman2/quotes/203973516/composite TECH -0.03%

Media and Investor Relations

Contact: David Clair, Senior Director, Investor Relations and Corporate Development
Phone: 612-656-4416
Email: david.clair@bio-techne.com

About Luminary Therapeutics Luminary Therapeutics is a pre-clinical cell therapy company developing next generation non-viral autologous cell treatments for cancers and autoimmune diseases. Luminary's primary focus is to develop CAR T and other next generation cell therapies that address the antigen escape issue present with existing therapies. Luminary utilizes Bio-Techne's TcBuster [™] transposon technology to reduce safety concerns, costs, and time delays associated with viral based cell therapies. Located in Minneapolis, Luminary's team is comprised of cellular therapy veterans, industry leaders, and world-renowned cancer geneticist leaders from top biotech and consulting organizations. Luminary seeks novel next generation licensing opportunities with strong intellectual property (IP) for the treatment of solid tumors and in underserved disorders.

For more information visit  www.luminarytx.com

Media and Investor Relations

Contact: Jeff Liter, CEO
Telephone: 1.612.309.7653
Email: j.liter@luminarytx.com

Cision
View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-techne-and-luminary-therapeutics-sign-license-agreement-for-use-of-bio-technes-tcbuster-for-the-development-of-luminarys-car-t-cell-therapies-301232431.html

SOURCE Bio-Techne Corporation

COMTEX_381582626/2454/2021-02-23T07:00:10

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/203973516/composite
US : U.S.: Nasdaq
$ 423.71
-0.13 -0.03%
Volume: 179,798
April 22, 2021 4:00p
P/E Ratio
96.62
Dividend Yield
0.30%
Market Cap
$16.44 billion
Rev. per Employee
$321,170
loading...
/zigman2/quotes/203973516/composite
US : U.S.: Nasdaq
$ 423.71
-0.13 -0.03%
Volume: 179,798
April 22, 2021 4:00p
P/E Ratio
96.62
Dividend Yield
0.30%
Market Cap
$16.44 billion
Rev. per Employee
$321,170
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.